CD200 and acute myeloid leukemia: In pediatric AML and B-ALL, overexpression of CD200, along with other receptors such as CD123 and CD56, on leukemic cells and leukemia stem cells has been associated with adverse prognostic features and poorer clinical outcomes [45,46].